Corcept Therapeutics Incorporated (0I3Q.L)
USD 57.41
(4.74%)
USD 57.41
(4.74%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 621.51 Million USD | 6.53% |
| 2022 | 583.43 Million USD | 37.68% |
| 2021 | 423.75 Million USD | -25.88% |
| 2020 | 571.73 Million USD | 38.66% |
| 2019 | 412.31 Million USD | 32.28% |
| 2018 | 311.69 Million USD | 41.33% |
| 2017 | 220.53 Million USD | 220.77% |
| 2016 | 68.75 Million USD | 32.38% |
| 2015 | 51.93 Million USD | 49.98% |
| 2014 | 34.63 Million USD | -45.1% |
| 2013 | 63.07 Million USD | -36.39% |
| 2012 | 99.16 Million USD | 148.95% |
| 2011 | 39.83 Million USD | 58.67% |
| 2010 | 25.1 Million USD | 2.42% |
| 2009 | 24.51 Million USD | 23.95% |
| 2008 | 19.77 Million USD | 11.45% |
| 2007 | 17.74 Million USD | 79.2% |
| 2006 | 9.9 Million USD | -67.16% |
| 2005 | 30.15 Million USD | -36.87% |
| 2004 | 47.77 Million USD | 305.5% |
| 2003 | 11.78 Million USD | -45.95% |
| 2002 | 21.79 Million USD | -10.16% |
| 2001 | 24.25 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 655.93 Million USD | 5.54% |
| 2024 Q3 | 784.25 Million USD | 9.75% |
| 2024 Q2 | 714.55 Million USD | 8.94% |
| 2023 FY | 621.51 Million USD | 6.53% |
| 2023 Q3 | 594.02 Million USD | 13.23% |
| 2023 Q4 | 621.51 Million USD | 4.63% |
| 2023 Q1 | 617.84 Million USD | 5.9% |
| 2023 Q2 | 524.62 Million USD | -15.09% |
| 2022 Q4 | 583.43 Million USD | 9.41% |
| 2022 Q1 | 468.12 Million USD | 10.47% |
| 2022 FY | 583.43 Million USD | 37.68% |
| 2022 Q2 | 496.36 Million USD | 6.03% |
| 2022 Q3 | 533.25 Million USD | 7.43% |
| 2021 FY | 423.75 Million USD | -25.88% |
| 2021 Q2 | 568.48 Million USD | 2.91% |
| 2021 Q1 | 552.39 Million USD | -3.38% |
| 2021 Q4 | 423.75 Million USD | -27.61% |
| 2021 Q3 | 585.39 Million USD | 2.98% |
| 2020 Q3 | 534.12 Million USD | 7.29% |
| 2020 Q1 | 445.49 Million USD | 8.05% |
| 2020 Q2 | 497.82 Million USD | 11.75% |
| 2020 Q4 | 571.73 Million USD | 7.04% |
| 2020 FY | 571.73 Million USD | 38.66% |
| 2019 FY | 412.31 Million USD | 32.28% |
| 2019 Q2 | 328.67 Million USD | 2.64% |
| 2019 Q1 | 320.21 Million USD | 2.73% |
| 2019 Q3 | 367.02 Million USD | 11.67% |
| 2019 Q4 | 412.31 Million USD | 12.34% |
| 2018 Q1 | 242.97 Million USD | 10.17% |
| 2018 Q4 | 311.69 Million USD | 3.98% |
| 2018 Q3 | 299.75 Million USD | 9.25% |
| 2018 Q2 | 274.38 Million USD | 12.93% |
| 2018 FY | 311.69 Million USD | 41.33% |
| 2017 Q2 | 86.53 Million USD | 14.86% |
| 2017 FY | 220.53 Million USD | 220.77% |
| 2017 Q4 | 220.53 Million USD | 99.27% |
| 2017 Q3 | 110.67 Million USD | 27.89% |
| 2017 Q1 | 75.33 Million USD | 9.58% |
| 2016 Q3 | 62.93 Million USD | 10.72% |
| 2016 Q4 | 68.75 Million USD | 9.25% |
| 2016 Q1 | 52.91 Million USD | 1.88% |
| 2016 FY | 68.75 Million USD | 32.38% |
| 2016 Q2 | 56.83 Million USD | 7.42% |
| 2015 FY | 51.93 Million USD | 49.98% |
| 2015 Q3 | 48.37 Million USD | 0.05% |
| 2015 Q1 | 48.22 Million USD | 39.25% |
| 2015 Q4 | 51.93 Million USD | 7.36% |
| 2015 Q2 | 48.35 Million USD | 0.27% |
| 2014 Q2 | 44.39 Million USD | -15.98% |
| 2014 Q1 | 52.83 Million USD | -16.24% |
| 2014 FY | 34.63 Million USD | -45.1% |
| 2014 Q4 | 34.63 Million USD | -6.81% |
| 2014 Q3 | 37.15 Million USD | -16.29% |
| 2013 Q1 | 88.14 Million USD | -11.12% |
| 2013 FY | 63.07 Million USD | -36.39% |
| 2013 Q2 | 79.68 Million USD | -9.59% |
| 2013 Q3 | 71.05 Million USD | -10.83% |
| 2013 Q4 | 63.07 Million USD | -11.23% |
| 2012 FY | 99.16 Million USD | 148.95% |
| 2012 Q4 | 99.16 Million USD | -6.03% |
| 2012 Q3 | 105.52 Million USD | 173.25% |
| 2012 Q1 | 42.88 Million USD | 7.67% |
| 2012 Q2 | 38.61 Million USD | -9.95% |
| 2011 Q3 | 46.37 Million USD | -12.03% |
| 2011 FY | 39.83 Million USD | 58.67% |
| 2011 Q2 | 52.72 Million USD | -11.89% |
| 2011 Q1 | 59.83 Million USD | 138.36% |
| 2011 Q4 | 39.83 Million USD | -14.11% |
| 2010 Q3 | 29.7 Million USD | -17.72% |
| 2010 Q4 | 25.1 Million USD | -15.47% |
| 2010 Q2 | 36.09 Million USD | 87.85% |
| 2010 FY | 25.1 Million USD | 2.42% |
| 2010 Q1 | 19.21 Million USD | -21.6% |
| 2009 Q4 | 24.51 Million USD | 110.94% |
| 2009 Q1 | 21.16 Million USD | 7.05% |
| 2009 Q2 | 15.61 Million USD | -26.26% |
| 2009 Q3 | 11.62 Million USD | -25.56% |
| 2009 FY | 24.51 Million USD | 23.95% |
| 2008 Q2 | 27.84 Million USD | -14.16% |
| 2008 Q4 | 19.77 Million USD | -19.94% |
| 2008 Q3 | 24.69 Million USD | -11.29% |
| 2008 Q1 | 32.43 Million USD | 82.81% |
| 2008 FY | 19.77 Million USD | 11.45% |
| 2007 Q4 | 17.74 Million USD | -15.92% |
| 2007 FY | 17.74 Million USD | 79.2% |
| 2007 Q2 | 12.93 Million USD | -14.98% |
| 2007 Q3 | 21.1 Million USD | 63.22% |
| 2007 Q1 | 15.2 Million USD | 53.59% |
| 2006 Q2 | 18.17 Million USD | -29.03% |
| 2006 FY | 9.9 Million USD | -67.16% |
| 2006 Q3 | 12.64 Million USD | -30.4% |
| 2006 Q4 | 9.9 Million USD | -21.7% |
| 2006 Q1 | 25.6 Million USD | -15.1% |
| 2005 Q2 | 38.13 Million USD | -9.05% |
| 2005 Q3 | 34.32 Million USD | -10.0% |
| 2005 Q4 | 30.15 Million USD | -12.14% |
| 2005 Q1 | 41.92 Million USD | -12.23% |
| 2005 FY | 30.15 Million USD | -36.87% |
| 2004 Q1 | 10.28 Million USD | -12.72% |
| 2004 Q3 | 52.48 Million USD | -6.48% |
| 2004 Q2 | 56.12 Million USD | 445.8% |
| 2004 FY | 47.77 Million USD | 305.5% |
| 2004 Q4 | 47.77 Million USD | -8.99% |
| 2003 FY | 11.78 Million USD | -45.95% |
| 2003 Q4 | 11.78 Million USD | 0.0% |
| 2002 FY | 21.79 Million USD | -10.16% |
| 2001 FY | 24.25 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 90.916% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -214.844% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 48.151% |
| Evolus, Inc. | 188.99 Million USD | -228.848% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 79.214% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 94.225% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 33.678% |
| uniQure N.V. | 831.68 Million USD | 25.271% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -302.573% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -275.53% |
| bluebird bio, Inc. | 619.16 Million USD | -0.381% |
| Abeona Therapeutics Inc. | 64 Million USD | -871.09% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 83.772% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 20.101% |
| Dynavax Technologies Corporation | 997.09 Million USD | 37.667% |
| Editas Medicine, Inc. | 499.15 Million USD | -24.514% |
| FibroGen, Inc. | 423.52 Million USD | -46.747% |
| Geron Corporation | 394.07 Million USD | -57.715% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 40.766% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 97.671% |
| Illumina, Inc. | 10.11 Billion USD | 93.853% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 20.354% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1010.863% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 80.885% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -393.879% |
| Adicet Bio, Inc. | 207.29 Million USD | -199.822% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 80.962% |
| Insmed Incorporated | 1.32 Billion USD | 53.264% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 52.227% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 81.478% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -846.136% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 55.889% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.233% |
| Waters Corporation | 4.62 Billion USD | 86.567% |
| Zoetis Inc. | 14.28 Billion USD | 95.649% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.37% |
| Biogen Inc. | 26.84 Billion USD | 97.685% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -275.948% |
| Nektar Therapeutics | 398.03 Million USD | -56.147% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -68.666% |
| Perrigo Company plc | 10.8 Billion USD | 94.25% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -5.658% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -179.326% |
| Verastem, Inc. | 149.71 Million USD | -315.125% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 97.266% |
| Imunon, Inc. | 21.91 Million USD | -2735.638% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2098.318% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -202.006% |
| Homology Medicines, Inc. | 47.05 Million USD | -1220.775% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.121% |
| OPKO Health, Inc. | 2.01 Billion USD | 69.105% |
| Exelixis, Inc. | 2.94 Billion USD | 78.877% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 64.142% |
| TG Therapeutics, Inc. | 329.58 Million USD | -88.574% |
| Incyte Corporation | 6.78 Billion USD | 90.836% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 66.128% |